Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Nitric oxide donors |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism mini-dystrophin stimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date29 Jun 2022 |
Sponsor / Collaborator |
Start Date29 Apr 2021 |
Sponsor / Collaborator |
Start Date15 Oct 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Intravenous citrulline | Acute Lung Injury More | Phase 3 |
L-Citrulline | Atrioventricular Septal Defect More | Phase 3 |
Muscular dystrophy gene therapy(Asklepion Pharmaceuticals LLC) ( mini-dystrophin ) | Muscular Dystrophy, Duchenne More | Pending |